Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.
about
Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patientsPharmacologic therapy for inflammatory bowel disease refractory to steroidsCharacterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveysA medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases.Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease.A mechanistic review on plant-derived natural compounds as dietary supplements for prevention of inflammatory bowel disease.Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort.Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan.Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.Combining genetic and nongenetic biomarkers to realize the promise of pharmacogenomics for inflammatory diseases.Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease.Indian Society of Gastroenterology consensus statements on Crohn's disease in India.Pharmacological therapy of spondyloarthritis.Biologic agents for IBD: practical insights.Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.Comparable outcomes of the consistent use versus switched use of anti- tumor necrosis factor agents in postoperative recurrent Crohn's disease following ileocolonic resection.Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab.Management of patients with inflammatory bowel disease and spondyloarthritis.Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment.Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD.Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn's disease.Regulatory role of NKG2D+ NK cells in intestinal lamina propria by secreting double-edged Th1 cytokines in ulcerative colitis.Novel, Anti-hTNF-α Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development.Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases.Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis.Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.Anti-TNFα Treatment After Surgical Resection for Crohn's Disease Is Effective Despite Previous Pharmacodynamic Failure.Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease.Approach to Optimize Anti-TNF-α Therapy in Patients With IBD.Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease.Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location?Crude leaf extracts of Piperaceae species downmodulate inflammatory responses by human monocytes.
P2860
Q26748630-197C362E-E53A-442D-A79F-11D2AB593F21Q26796415-FD32D65E-86C3-4503-A25E-B924E285BF04Q26862821-FBCE0BC8-58B0-4282-99A2-DF8FBD5760B0Q34353032-D1A9B9C8-B11A-45C5-9A81-BAB7CE524241Q35188609-D6024060-2127-4A80-A074-22E460829DC9Q35599763-09877D16-FCEC-4652-A84A-9352144E4D98Q35901531-BC66493A-FF7C-40A0-8134-65C726E0A168Q36059784-1E17C672-282E-4011-86F4-296EFA3847EFQ36089928-EB47D5B2-DFEB-4633-9F5F-D3BB079A2DFAQ36689512-0EB4ED8E-E575-4E61-B02A-BEF3CD757EBAQ38248218-3DA5A27C-A055-46ED-A0DA-D498E90BD2E7Q38286234-F664C41B-B66D-4617-BF61-DD83408EC608Q38317338-3BA9A25F-2A72-411B-BFB7-E5D41E5D3BFAQ38378837-66034E4F-CAE0-4610-89AF-F75F262569DCQ38527552-DC865642-FF9F-4333-A0DC-11D51767F010Q38568898-74F99854-9F8D-4188-BB28-2D485A9D4E6BQ38619950-8E08688F-AFC8-41B2-8CAB-E48968C0B402Q38719570-D412D9F8-B87F-48DC-9D25-06C6C362495FQ38822920-2E841C27-9733-4636-A192-025C70301707Q38850063-115681AE-7928-4F6B-A469-F3E15771FC05Q38888227-E87C85A2-ABAF-4FFE-A21F-68C25758BB9CQ39012932-C159ED78-4B1B-46E5-B3FB-52A1D4408CD0Q39435409-DDBC5B97-9F92-4389-8A2E-1C3F545731F0Q39542719-664AD9A6-1E44-42F0-ACEF-6533811505DAQ39596651-AB952281-C380-414C-A65B-0F5BFD25E2EAQ40054186-32D7DC4E-8798-484E-A2B9-467150429577Q42320550-2B001A2F-F627-4429-B50E-E217FCD99064Q46003614-68833A4D-5D7B-42EE-9F60-57FB6DD56AC4Q47142918-F3674F64-8906-46AD-9FA5-17DF88CF9146Q47147682-29DC5F5F-C18D-441D-A1C8-A7FCA774DF4BQ47221249-3C9BFC25-2546-4B15-B28E-30EA618EF48DQ47325212-434A3BE3-1173-45D8-B77A-BDB747EC7B65Q47557672-B51AD429-A5AA-4B26-8BFC-184AAF2281B5Q48265538-41BB0C26-5148-431E-AAB5-112992FF1B4BQ49101989-AE1C00BE-D531-43DB-94E2-F4A824E00297Q49315243-ABA1B448-3DA1-4E08-9889-3E6C57D8203CQ50713607-22891F4E-B640-4F53-A2CD-DBA4304A54B6Q51064245-86E7124E-21AE-4370-AAFD-C491EDA7E084Q51534305-BE5CF2C6-8DCB-4B35-AB9E-DCEAC00FA972Q55433516-DF2C3294-D99F-45B2-8E57-F9FEE3BDA68B
P2860
Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Systematic review with network ...... treatment of Crohn's disease.
@en
type
label
Systematic review with network ...... treatment of Crohn's disease.
@en
prefLabel
Systematic review with network ...... treatment of Crohn's disease.
@en
P2093
P2860
P356
P1476
Systematic review with network ...... treatment of Crohn's disease.
@en
P2093
A G Singal
A K Waljee
A R Deshpande
B J Elmunzer
D A Sussman
P D R Higgins
R W Stidham
P2860
P304
P356
10.1111/APT.12749
P407
P577
2014-04-20T00:00:00Z